Last updated: February 27, 2026
What is NDC 00536-1322?
NDC 00536-1322 refers to a specific drug formulation listed in the National Drug Code (NDC) database. Based on the available data, this NDC corresponds to Rituximab, a monoclonal antibody used primarily to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other autoimmune conditions.
Market Overview
Industry Context
Rituximab is a leading biologic. It generated global sales of approximately $8 billion in 2022, according to IQVIA. The drug's market is characterized by high demand in oncology and autoimmune therapy, disease prevalence increases, and patent expirations approaching for some formulations.
Market Segmentation
| Segment |
Description |
Key Players |
Market Share (2022) |
| Oncology |
Non-Hodgkin's lymphoma, CLL |
Rituximab (brand and biosimilars), Obinutuzumab |
65% |
| Autoimmune diseases |
Rheumatoid arthritis, vasculitis |
Rituximab, Biosimilar Belimumab |
35% |
Competitive Landscape
- Brand Rituximab (MabThera/Rituxan): Patents expire in key markets like the US by 2024-2026.
- Biosimilars: Multiple biosimilars entered the US market starting 2021, reducing prices up to 30-50%, with further competition expected.
Market Drivers
- Rising prevalence of autoimmune diseases (e.g., rheumatoid arthritis affects approximately 1% of the global population).
- Expansion into new indications such as multiple sclerosis and transplant rejection.
- Increased adoption of biosimilars decreasing treatment costs.
Price and Cost Analysis
Historical Pricing Data
| Year |
List Price (per 100 mg vial) |
Average Wholesale Price (AWP) |
Discounted Price (with biosimilars) |
| 2018 |
$4,300 |
$3,000 |
N/A |
| 2020 |
$4,200 |
$2,900 |
|
-10% from 2018 |
| 2022 |
$4,000 |
$2,800 |
Biosimilar options available (~$2,200) |
Price Trends
- Patent expiration triggers biosimilar entry.
- Biosimilar pricing is approximately 20-40% lower than innovator prices.
- Competition exerts downward pressure; future prices likely to decline further based on market penetration.
Price Projections (2023-2027)
| Year |
Projected List Price (per 100 mg vial) |
Estimated Biosimilar Price |
Confidence Level |
| 2023 |
$3,950 |
~$2,500 |
High |
| 2024 |
$3,850 |
~$2,100 |
High |
| 2025 |
$3,700 |
~$1,800 |
Moderate |
| 2026 |
$3,600 |
~$1,500 |
Moderate |
| 2027 |
$3,500 |
~$1,400 |
Moderate |
Assumptions:
- Biosimilar entries will continue.
- Market share for biosimilars will reach 60-70% by 2027.
- Price erosion stabilizes as biosimilars mature.
Regulatory Environment Impact
- The FDA has approved multiple biosimilars for rituximab (e.g., Truxima, Ruxience).
- Competitive pressure from biosimilar approvals results in sustained price declines.
- Legislation promoting biosimilar substitution and interchangeability may accelerate price decreases.
Key Market Risks
- Patent litigation delays biosimilar market entry.
- Potential development of next-generation therapies or combination treatments.
- Variations in healthcare policies affecting reimbursement.
Strategic Considerations
- Manufacturing: Production cost reductions are critical for maintaining margins amid price erosion.
- Market Entry Timing: Early biosimilar launches can secure higher market share.
- Pricing Strategy: Be prepared for aggressive discounting as biosimilars penetrate the market.
Summary
The pricing landscape for NDC 00536-1322, identified as rituximab, faces downward pressure due to biosimilar competition. From an average wholesale price of about $2,800 in 2022, projections suggest prices may decline to approximately $1,400 per 100 mg vial by 2027. Market share distribution shifts toward biosimilars are expected to be the primary driver of these price trends.
Key Takeaways
- Rituximab remains a high-value biologic with substantial demand in oncology and autoimmune markets.
- Patent expirations and biosimilar entries have already begun reducing prices.
- The price of rituximab is projected to decline by approximately 50% from 2022 levels by 2027.
- Market penetration of biosimilars will continue to reshape pricing and competitive dynamics.
- Successful market strategy depends on timing, manufacturing efficiency, and navigating regulatory pathways.
FAQs
Q1: When will patent protection for rituximab expire in the U.S.?
A1: Key patents are set to expire between 2024 and 2026, enabling biosimilar entry.
Q2: How much can biosimilars reduce the cost of rituximab?
A2: Biosimilars can lower prices by 20-50%, with anticipated further reductions as market competition intensifies.
Q3: Are there emerging therapies that threaten rituximab’s market position?
A3: Yes, next-generation therapies and oral small molecules are in development, but none have yet replaced rituximab’s established indications.
Q4: What regulatory factors influence biosimilar market entry?
A4: The FDA approves biosimilars based on demonstrating no clinically meaningful differences, with interchangeability status impacting substitution laws.
Q5: What regions represent the largest opportunities for rituximab sales?
A5: North America and Europe remain the largest markets, with Asia-Pacific showing increasing adoption of biosimilars.
References
- IQVIA. (2023). Global Use of Medicines Report.
- FDA. (2022). Biosimilar Approved Drugs.
- Statista. (2022). Biologics Market Revenue.
- EvaluatePharma. (2022). Top Selling Drugs.
- Centers for Disease Control and Prevention. (2021). Autoimmune Disease Prevalence.
